Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jul/Aug;81(6):506-512.
doi: 10.1097/PSY.0000000000000712.

Moderators of Response to Cognitive Behavior Therapy for Major Depression in Patients With Heart Failure

Stephen F Smagula  1 , Kenneth E Freedland, Brian C Steinmeyer, Meredith J Wallace, Robert M Carney, Michael W Rich
Affiliations
Randomized Controlled Trial

Moderators of Response to Cognitive Behavior Therapy for Major Depression in Patients With Heart Failure

Stephen F Smagula et al. Psychosom Med. 2019 Jul/Aug.

Erratum in

Abstract

Objective: Although cognitive behavior therapy (CBT) is efficacious for major depression in patients with heart failure (HF), approximately half of patients do not remit after CBT. To identify treatment moderators that may help guide treatment allocation strategies and serve as new treatment targets, we performed a secondary analysis of a randomized clinical trial. Based on evidence of their prognostic relevance, we evaluated whether clinical and activity characteristics moderate the effects of CBT.

Methods: Participants were randomized to enhanced usual care (UC) alone or CBT plus enhanced UC. The single-blinded outcomes were 6-month changes in Beck Depression Inventory total scores and remission (defined as a Beck Depression Inventory ≤ 9). Actigraphy was used to assess daily physical activity patterns. We performed analyses to identify the specific activity and clinical moderators of the effects of CBT in 94 adults (mean age = 58, 49% female) with HF and major depressive disorder.

Results: Patients benefited more from CBT (versus UC) if they had the following: more medically severe HF (i.e., a higher New York Heart Association class or a lower left ventricular ejection fraction), more stable activity patterns, wider active periods, and later evening settling times. These individual moderator effects were small (|r| = 0.10-0.21), but combining the moderators yielded a medium moderator effect size (r = 0.38; 95% CI = 0.20-0.52).

Conclusions: These findings suggest that increasing the cross-daily stability of activity patterns, and prolonging the daily active period, might help increase the efficacy of CBT. Given moderating effects of HF severity measures, research is also needed to clarify and address factors in patients with less severe HF that diminish the efficacy of CBT.

Clinical trial registration: clinicaltrials.gov identifier: NCT01028625.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Average depression symptom changes in the two treatments depending on the value of the indiviudal moderators.
Note the difference between the two treatment arms in terms of the level of depression symptom changes varies across the moderator values, e.g., there is less overlap between the two lines at lower values of LVEF and higher values NYHA grades.
Figure 2.
Figure 2.. Average depression symptom changes in the two treatments depending on the value of the combined moderators.
Note that CBT-UC separaton is greatest at lower values of the full cominbed moderator.
Figure 3.
Figure 3.. Remission rates stratified by treatment arm and the cross-point of the full combined moderator.
See this image and copyright information in PMC

Comment in

References

    1. Koenig HG. Depression in hospitalized older patients with congestive heart failure. General hospital psychiatry 1998;20(1):29–43. - PubMed
    1. Freedland KE, Rich MW, Skala JA, Carney RM, Davila-Roman VG, Jaffe AS. Prevalence of depression in hospitalized patients with congestive heart failure. Psychosomatic medicine 2003;65(1):119–128. - PubMed
    1. Tinetti ME, McAvay GJ, Chang SS, et al. Contribution of multiple chronic conditions to universal health outcomes. J Am Geriatr Soc 2011;59(9):1686–1691. - PMC - PubMed
    1. O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. Journal of the American College of Cardiology 2010;56(9):692–699. - PMC - PubMed
    1. Angermann CE, Gelbrich G, Stork S, et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. Jama 2016;315(24):2683–2693. - PubMed

Publication types

Associated data